Tocilizumab (anti-IL-6R)

Catalog No.A2012        Batch: A201203

Print

Technical Data

CAS No. ‎375823-41-9
Formulation PBS buffer, pH 7.2
Isotype Human IgG1
Source CHO cells
Storage
(From the date of receipt)		 Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles
Purity 98.4%
Protein concentration 5 mg/ml
Endotoxin Level <1 EU/mg

Biological Activity

Description Tocilizumab (anti-IL-6R) is a humanized monoclonal antibody that binds to the interleukin-6 receptor, MW: 148 KD.
Targets
IL-6R [1]
In vitro

After adding tocilizumab at different concentrations into HMO6 and CHME5 cells stimulated by F3-CM or with IL6, the expression levels of anti-inflammatory M2 markers (CD206 and Arg1) are decreased, as well as the levels of both phosphorylated JAK2 and STAT3.[1]
In vivo

Tocilizumab can block JAK2/STAT3 activation and impede brain metastasis (BM) of A549-F3 cells in vivo.[1]

Protocol (Only for Reference)

Cell Assay:

  • HMO6 and CHME5 cells with control media or F3-CM alone or F3-CM were treated with Tocilizumab (2.5 μg/ml for 24 h) or with IL6 (200 ng/ml for 24 h) alone or IL6-supplemented with Tocilizumab. Western blot analysis of p-JAK2, JAK2, p-STAT3, and STAT3 in HMO6 and CHME5 cells were conducted.
Animal Study:

  • Animal Models: Nude mice of brain metastasis models
    Dosages: 5 mg/kg
    Administration: i.p.
    Reference: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8864012/
     

Selleck's Tocilizumab (anti-IL-6R) has been cited by 50 publications

AKT and EZH2 inhibitors kill TNBCs by hijacking mechanisms of involution [ Nature, 2024, 10.1038/s41586-024-08031-6] PubMed: 39385030
Development of a chimeric cytokine receptor that captures IL-6 and enhances the antitumor response of CAR-T cells [ Cell Rep Med, 2024, S2666-3791(24)00195-2] PubMed: 38670095
CALB2 drives pancreatic cancer metastasis through inflammatory reprogramming of the tumor microenvironment [ J Exp Clin Cancer Res, 2024, 43(1):277] PubMed: 39358777
Cells in the Polyaneuploid Cancer Cell State are Pro-Metastatic [ bioRxiv, 2024, 2024.07.12.603285] PubMed: 39071340
Autoimmunity in Down's syndrome via cytokines, CD4 T cells and CD11c+ B cells [ Nature, 2023, 615(7951):305-314] PubMed: 36813963
Autoimmunity in Down's syndrome via cytokines, CD4 T cells and CD11c+ B cells [ Nature, 2023, 615(7951):305-314] PubMed: 36813963
Autoimmunity in Down's syndrome via cytokines, CD4 T cells and CD11c+ B cells [ Nature, 2023, 615(7951):305-314] PubMed: 36813963
Autoimmunity in Down's syndrome via cytokines, CD4 T cells and CD11c+ B cells [ Nature, 2023, 615(7951):305-314] PubMed: 36813963
Peripheral helper-T-cell-derived CXCL13 is a crucial pathogenic factor in idiopathic multicentric Castleman disease [ Nat Commun, 2023, 14(1):6959] PubMed: 37907518
Anti-inflammatory effect of interleukin-6 highly enriched in secretome of two clinically relevant sources of mesenchymal stromal cells [ Front Cell Dev Biol, 2023, 11:1244120] PubMed: 37745306

FOR RESEARCH USE ONLY. NOT FOR USE IN HUMANS.

Specific storage and handling information for each product is indicated on the product datasheet. Most Selleck products are stable under the recommended conditions. Products are sometimes shipped at a temperature that differs from the recommended storage temperature. Short-term storage of many products are stable in the short-term at temperatures that differ from that required for long-term storage.
We ensure that the product is shipped under conditions that will maintain the quality of the reagents. Upon receipt of the product, follow the storage recommendations on the product data sheet.